Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.20
-0.03 (-1.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $430.2M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.8B
P/E
15.7x
↓EV/EBITDA
5.5x
↓ROE
3.8%
↑Gross Margin
66.0%
↑Debt/Equity
0.59
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.8%
FCF CAGR
+16.8%
FCF margin
12.4%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.31B · net income $618.7M · FCF $780.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.31B | $6.31B | $6.06B | $6.14B | $5.98B |
| Net Income | $618.7M | $618.7M | $471.9M | $532.6M | $604.8M |
| EBITDA | $2.47B | $2.47B | $2.19B | $2.08B | $1.81B |
| EPS | 0.13 | 0.13 | 0.13 | 0.14 | 0.17 |
| Gross Margin | 66.0% | 66.0% | 66.7% | 68.4% | 69.2% |
| Operating Margin | 19.9% | 19.9% | 21.3% | 16.7% | 15.9% |
| Net Margin | 9.8% | 9.8% | 7.8% | 8.7% | 10.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.59 | 0.59 | 0.73 | 0.67 | 0.89 |
| Current Ratio | 1.53 | 1.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $780.4M | $780.4M | $-1.54B | $430.2M | $490.1M |
| Returns | |||||
| ROE | 3.8% | 3.8% | 3.3% | 4.3% | 5.9% |
| Valuation | |||||
| P/E | 15.71 | 15.71 | 16.91 | 24.91 | 21.23 |
| EV/EBITDA | 5.46 | 5.46 | 6.10 | 8.89 | 10.83 |
| P/B | 0.53 | 0.53 | 0.56 | 1.06 | 1.26 |
| Growth & Yield | |||||
| Revenue Growth | 4.1% | 4.1% | -1.3% | 2.7% | — |
| EPS Growth | -0.3% | -0.3% | -12.2% | -17.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.0%
EPS terminal req.
$0.20
Spread vs growth
-16.3%
5Y implied EPS CAGR
13.6%
EPS terminal req.
$0.24
Spread vs growth
-13.9%
10Y implied EPS CAGR
11.8%
EPS terminal req.
$0.38
Spread vs growth
-12.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.8%
Start / end P/E
17.1x → 17.6x
EPS bridge
0.13 → 0.13
Residual
-0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.